AM-Pharma's Phase II sepsis readout triggers Pfizer's takeout option

AM-Pharma B.V. (Bunnik, the Netherlands) reported mixed data on Friday from the Phase II STOP-AKI trial of recAP to treat

Read the full 207 word article

User Sign In